Zalbin data underscore new option for hep C patients

Human Genome Sciences helped burnish the reputation of its experimental therapy Zalbin as an alternative option for hepatitis C patients. HGS reported that a mid-stage trial demonstrated that a monthly dose of the drug was as effective as the current standard in treating the ailment. The company noted that the data showed that the drug could be an important option for hep C patients with genotypes 2 and 3, which typically are easier to treat than genotype 1. The drug, which has already generated more than $200 million in milestone payments from Novartis, has been through Phase III and has been filed for approval with the FDA. The PDUFA date is October 4. HGS release | Report  

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.